Stockscreener 앱 받기
2.54
3.67%
0.09
시간 외 거래:
2.54
전일 마감가:
$2.45
열려 있는:
$2.43
하루 거래량:
2.30M
Relative Volume:
1.31
시가총액:
$718.13M
수익:
-
순이익/손실:
$-125.04M
주가수익비율:
-1.427
EPS:
-1.78
순현금흐름:
$-122.99M
1주 성능:
-0.78%
1개월 성능:
-3.79%
6개월 성능:
+25.12%
1년 성능:
+35.83%
1일 변동 폭
$2.38
$2.59
1주일 범위
$2.38
$2.68
52주 변동 폭
$1.64
$3.45
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
ERAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.54 | 718.13M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $994,000 in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Fmr LLC Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Shares Gap UpShould You Buy? - MarketBeat
The Manufacturers Life Insurance Company Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Stock Position Raised by Charles Schwab Investment Management Inc. - MarketBeat
Clear Street starts Erasca with Buy, sets $5 price target By Investing.com - Investing.com UK
Clear Street starts Erasca with Buy, sets $5 price target - Investing.com
Erasca, Inc. (NASDAQ:ERAS) Holdings Boosted by Frazier Life Sciences Management L.P. - MarketBeat
One Erasca Insider Raised Stake By 14% In Previous Year - Simply Wall St
Janus Henderson Group PLC Has $11.20 Million Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Walleye Capital LLC Has $2.59 Million Stock Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Stellantis, PG&E And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Fred Alger Management LLC Acquires New Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Sio Capital Management LLC Decreases Holdings in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Principal Financial Group Inc. - Defense World
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Receives $6.10 Average PT from Brokerages - Defense World
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Jefferies Financial Group Begins Coverage on Erasca (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Erasca (NASDAQ:ERAS) Now Covered by Jefferies Financial Group - MarketBeat
Erasca initiated with a Buy at Jefferies - TipRanks
Jefferies bullish on Erasca stock as promising RAS-targeted therapies drive upside - Investing.com India
What is HC Wainwright’s Estimate for Erasca FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
Erasca (NASDAQ:ERAS) Earns “Buy” Rating from HC Wainwright - Defense World
Significant Stake Increase by T. Rowe Price in Erasca Inc - GuruFocus.com
Creative Planning Increases Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. Reports Strong Progress in Oncology Pipeline - TipRanks
Erasca's (ERAS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Erasca Reports Third Quarter 2024 Business Updates and Financial Results - The Manila Times
Erasca Reports Strong Phase 1b Data, $463M Cash Position Extends Runway to 2027 | ERAS Stock News - StockTitan
Erasca to Present at Upcoming Investor Conferences - ForexTV.com
Erasca (ERAS) to Present at Three Major Healthcare Investor Conferences | ERAS Stock News - StockTitan
Erasca Insiders Added US$1.95m Of Stock To Their Holdings - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 3.8%Should You Buy? - MarketBeat
The Goldman Sachs Group Raises Erasca (NASDAQ:ERAS) Price Target to $3.50 - Defense World
Erasca (NASDAQ:ERAS) Trading Down 3.4%What's Next? - MarketBeat
Erasca Inc (NASDAQ: ERAS) Stock: Bulls Should Watch This - Stocks Register
Erasca stock gains momentum as Goldman sees potential in melanoma treatment - Investing.com Canada
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - MarketBeat
Erasca reports progress in melanoma treatment trials - Investing.com India
Erasca reports progress in melanoma treatment trials By Investing.com - Investing.com UK
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise - The Manila Times
Erasca, Inc. (NASDAQ:ERAS) Holdings Lowered by Exchange Traded Concepts LLC - Defense World
Stock Performance Spotlight: Erasca Inc (ERAS) Ends the Day at 2.81, Up by 2.18 - The Dwinnex
A look into Erasca Inc (ERAS)’s deeper side - SETE News
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth - Simply Wall St
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):